Patents by Inventor Gunhild Maelandsmo

Gunhild Maelandsmo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Poly (Alkyl Cyanoacrylate) Nanoparticles for Use in Treatment of Cancer
    Publication number: 20210113482
    Abstract: The invention is related to the field nanoparticles and medical use. In particular, it relates to cabazitaxel (CBZ) as active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer.
    Type: Application
    Filed: March 27, 2019
    Publication date: April 22, 2021
    Inventors: Yrr Mørch, Ruth Schmid, Einar Sulheim, Per Stenstad, Heidi Johnsen, Kirsten Sandvig, Gunhild Mælandsmo, Tore Skotland, Kjersti Flatmark
  • CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer
    Patent number: 5877308
    Abstract: Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to CAPL nucleic acid. Also disclosed are methods of inhibiting the expression of CAPL gene and methods of inhibiting metastatic cancer using CAPL-specific oligonucleotides.
    Type: Grant
    Filed: May 3, 1996
    Date of Patent: March 2, 1999
    Assignees: Hybridon, Inc., Norwegian Radium Hospital Research Foundation
    Inventors: Oystein Fodstad, Eivind Hovig, Olav Engebraaten, Gunhild Maelandsmo, Sudhir Agrawal, Eric von Hofe
  • CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer
    Patent number: 5872007
    Abstract: Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to CAPL nucleic acid. Also disclosed are methods of inhibiting the expression of CAPL gene and methods of inhibiting metastatic cancer using CAPL-specific oligonucleotides.
    Type: Grant
    Filed: July 14, 1995
    Date of Patent: February 16, 1999
    Assignee: Hybridon, Inc.
    Inventors: Oystein Fodstad, Eivind Hovig, Olav Engebraaten, Gunhild Maelandsmo, Sudhir Agrawal
  • CAPL-specific oligonucleotides and method of inhibiting metastatic cancer
    Patent number: 5789248
    Abstract: Disclosed are synthetic oligonucleotides having a nucleotide sequence complementary to CAPL nucleic acid. Also disclosed are methods of inhibiting the expression of CAPL gene and methods of inhibiting metastatic cancer using CAPL-specific oligonucleotides.
    Type: Grant
    Filed: February 16, 1996
    Date of Patent: August 4, 1998
    Assignees: Hybridon, Inc., Norwegian Radium Hospital Research Foundation
    Inventors: Oystein Fodstad, Eivind Hovig, Olav Engebraaten, Gunhild Maelandsmo, Sudhir Agrawal